Lantern Pharma (LTRN) vs Tvardi Therapeutics (TVRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lantern Pharma (LTRN) has outperformed Tvardi Therapeutics (TVRD) over the past year, losing 80.0% versus a loss of 97.3%. Over five years, LTRN leads with a -90.9% price change compared with -99.8% for TVRD. Tvardi Therapeutics is the larger company by market cap ($14.4 million vs $12.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LTRN | TVRD |
|---|---|---|
| Share price | $0.83 | $1.08 |
| Market cap | $12.40M | $14.41M |
| 1-day change | -8.79% | -1.82% |
| YTD return | -69.97% | -74.42% |
| 1-year return | -80.00% | -97.27% |
| 5-year return | -90.91% | -99.77% |
| EPS (TTM) | $-1.63 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.68 | $43.65 |
| 52-week low | $0.83 | $0.93 |
| Distance from 52-week high | -82.26% | -97.53% |
| Analyst consensus | none | buy |
| Avg. price target upside | +2008.43% | +756.48% |
| Average volume | 180.42K | 424.45K |
| Shares outstanding | 14.94M | 13.34M |
| Employees | 16 | 12 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LTRN has outperformed TVRD by 17.3 percentage points over the past year.
About Lantern Pharma
LTRN stock →Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.
Healthcare · Biotechnology · 16 employees
About Tvardi Therapeutics
TVRD stock →Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Healthcare · Biotechnology · 12 employees
LTRN vs TVRD FAQ
Which is bigger, Lantern Pharma or Tvardi Therapeutics?
Tvardi Therapeutics (TVRD) is larger, with a market capitalization of $14.41M compared with $12.40M for Lantern Pharma (LTRN).
Which stock has performed better over the past year, LTRN or TVRD?
LTRN returned -80.00% over the past 12 months, compared with -97.27% for TVRD (price return, excluding dividends). Past performance does not predict future results.
Are Lantern Pharma and Tvardi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.